Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04144699
Other study ID # HDV-CDD-190046
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2019
Est. completion date December 31, 2021

Study information

Verified date September 2021
Source Omron Healthcare Co., Ltd.
Contact Naoto Ohgami
Phone +81-75-925-2304
Email naoto.ogami@omron.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The WheezeScan sensitivity and specificity are set to statistically prove equal to or higher values than the predicate PulmoTrack device model 2020.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date December 31, 2021
Est. primary completion date November 30, 2021
Accepts healthy volunteers No
Gender All
Age group 3 Months to 8 Years
Eligibility Inclusion Criteria: Mild to moderate diagnosed or suspected asthma, bronchitis, or bronchiolitis patients who meet all of the following criteria are considered as eligible. 1. Does the subject have mild to moderate diagnosed or suspected asthma, bronchitis, or bronchiolitis? 2. Is the subject between the ages of 3 months to 8 years old? 3. Is the parent or legal guardian available, and capable and willing to give a consent on the child's behalf. Exclusion Criteria: The subjects will be excluded from the study, if they have any of the following criteria. 1. Does the subject have skin rashes or wounds on the chest? 2. Does the subject have known allergies or irritant contact dermatitis or having hypersensitive skin? 3. Does the subject have a defibrillator and/or pacemaker (which could interfere with the sounds to be detected)? 4. Does the subject have an allergy to disinfecting alcohol? 5. Does the subject have wheezes caused by not asthma, such as reflux esophagitis, pneumonia, vocal cord dysfunction, Tracheomatosis? 6. Does the subject have a heavy runny nose? 7. Is it difficult to hear auscultation due to the subject fussing, crying or vocalizing at data collection? 8. Is the subject having difficulty breathing or having severe symptoms? 9. Was the subject enrolled more than once for the same resulted breath sounds? - Note: The subject maybe enrolled once per arm (once wheezing, once non-wheezing).

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Tekton Research Beaumont Texas
United States PMG Research of Bristol Bristol Tennessee
United States Tekton Research Chamblee Georgia
United States PMG Research of Charleston Charleston South Carolina
United States University of Chicago Chicago Illinois
United States Children's Hospital Medical Center Cincinnati Ohio
United States Meridian Clinical Research, LLC Dakota Dunes South Dakota
United States PMG Research of Knoxville Jefferson City Tennessee
United States PMG Research of DuPage Joliet Illinois
United States University of Wisconsin Madison Wisconsin
United States Long Island Jewish Medical Center New York New York
United States PMG Research of Raleigh Raleigh North Carolina
United States Tekton Research San Antonio Texas
United States Tekton Research San Antonio Texas
United States PMG Research of Winston-Salem Winston-Salem North Carolina

Sponsors (4)

Lead Sponsor Collaborator
Omron Healthcare Co., Ltd. Children's Hospital Medical Center, Cincinnati, University of Chicago, University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the sensitivity and specificity of the Omron WheezeScan device The WheezeScan device will be compared to the gold standard, auscultation, which will be performed by a physician or a qualified healthcare professional with a minimum of 3 years' experience. All breath sounds will be recorded for comparison in case of discrepancy. Novemver 1, 2019 ~ November 30, 2021
See also
  Status Clinical Trial Phase
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Recruiting NCT05734261 - Forced Oscillations Technique During a Metacholine Test in Children N/A
Recruiting NCT06044051 - Dynamics of the Upper and Lower Airway Respiratory Microbiomes Associated With Severe Infant Asthma N/A
Completed NCT04896502 - Effectiveness of Telemedicine Home Assessments for Identification and Reduction of Asthma Triggers N/A
Completed NCT03503812 - Mitigating the Health Effects of Desert Dust Storms Using Exposure-Reduction Approaches N/A
Recruiting NCT06003569 - Reducing Asthma Attacks in Disadvantaged School Children With Asthma N/A
Not yet recruiting NCT05902702 - Isotonic Saline for Children With Bronchiolitis N/A
Not yet recruiting NCT05547477 - Continuous EMG Measurements in Children With Asthma During Sleep
Completed NCT04388098 - Oral Health Status of Asthmatic Children
Terminated NCT03586544 - Reducing Exercise-induced Bronchoconstriction in Children With Asthma and Obesity Phase 4
Recruiting NCT04821908 - Consequences of COVID 19 Pandemic on Childhood Asthma
Not yet recruiting NCT03277170 - Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations Phase 2
Enrolling by invitation NCT06239844 - Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English N/A
Not yet recruiting NCT05974917 - Serious gaMes as Emerging E-health Interventions for Young People With neurologicaL or rEspiratory disoRders
Not yet recruiting NCT05997784 - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Recruiting NCT05366309 - Performance and Adherence in Children Using Spacers N/A
Completed NCT05684926 - COVID-19 Pandemic Asthma Child Telerehabilitation Yoga N/A
Recruiting NCT04166344 - A mHealth Intervention to Improve Symptom Control in Children and Adolescents With Difficult-to-control Asthma N/A
Completed NCT05576142 - Oral Findings in Pediatric Patients With Allergic Rhinitis and/or Asthma
Completed NCT03673618 - Soluble Corn Fiber Supplementation for Asthma Phase 2